Bioportfolio Limited 03312883 true 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is internet website design and management. Digita Accounts Production Advanced 6.30.9574.0 true Mr Peter Douglas Barfoot 03312883 2024-04-01 2025-03-31 03312883 2025-03-31 03312883 bus:OrdinaryShareClass1 2025-03-31 03312883 bus:OrdinaryShareClass2 2025-03-31 03312883 core:RetainedEarningsAccumulatedLosses 2025-03-31 03312883 core:ShareCapital 2025-03-31 03312883 core:CurrentFinancialInstruments 2025-03-31 03312883 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 03312883 core:FurnitureFittingsToolsEquipment 2025-03-31 03312883 bus:FRS102 2024-04-01 2025-03-31 03312883 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 03312883 bus:FullAccounts 2024-04-01 2025-03-31 03312883 bus:RegisteredOffice 2024-04-01 2025-03-31 03312883 bus:Director1 2024-04-01 2025-03-31 03312883 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 03312883 bus:OrdinaryShareClass2 2024-04-01 2025-03-31 03312883 bus:EntityNoLongerTradingButTradedInPast 2024-04-01 2025-03-31 03312883 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 03312883 core:OfficeEquipment 2024-04-01 2025-03-31 03312883 countries:England 2024-04-01 2025-03-31 03312883 2024-03-31 03312883 core:FurnitureFittingsToolsEquipment 2024-03-31 03312883 2023-04-01 2024-03-31 03312883 2024-03-31 03312883 bus:OrdinaryShareClass1 2024-03-31 03312883 bus:OrdinaryShareClass2 2024-03-31 03312883 core:RetainedEarningsAccumulatedLosses 2024-03-31 03312883 core:ShareCapital 2024-03-31 03312883 core:CurrentFinancialInstruments 2024-03-31 03312883 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 03312883 core:FurnitureFittingsToolsEquipment 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 03312883

Bioportfolio Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

Dormant

 

Bioportfolio Limited

(Registration number: 03312883)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

2,462

2,462

Current assets

 

Debtors

5

198

198

Cash at bank and in hand

 

50

50

 

248

248

Creditors: Amounts falling due within one year

7

(7,049)

(7,049)

Net current liabilities

 

(6,801)

(6,801)

Net liabilities

 

(4,339)

(4,339)

Capital and reserves

 

Called up share capital

8

120

120

Retained earnings

(4,459)

(4,459)

Shareholders' deficit

 

(4,339)

(4,339)

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 1 May 2025
 

.........................................
Mr Peter Douglas Barfoot
Director

 

Bioportfolio Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Stafford House
10 Prince of Wales Road
Dorchester
Dorset
DT1 1PW

The principal place of business is:
Wessex Barn
8 Dorchester Road
Frampton
Dorchester
Dorset
DT2 9NB

These financial statements were authorised for issue by the director on 1 May 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

15% reducing balance basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Bioportfolio Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2024 - 1).

 

Bioportfolio Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 April 2024

30,670

30,670

At 31 March 2025

30,670

30,670

Depreciation

At 1 April 2024

28,208

28,208

At 31 March 2025

28,208

28,208

Carrying amount

At 31 March 2025

2,462

2,462

At 31 March 2024

2,462

2,462

5

Debtors

Current

2025
£

2024
£

Other debtors

198

198

 

198

198

6

Cash and cash equivalents

2025
£

2024
£

Cash at bank

50

50

7

Creditors

2025
£

2024
£

Due within one year

Other payables

5,346

5,346

Accruals

1,703

1,703

7,049

7,049

 

Bioportfolio Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

8

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary A Shares of £1 each

108

108

108

108

Ordinary B Shares of £1 each

12

12

12

12

120

120

120

120